158 related articles for article (PubMed ID: 33135516)
1. The role of PI3K inhibitors in the treatment of malignant lymphomas.
Berning P; Lenz G
Leuk Lymphoma; 2021 Mar; 62(3):517-527. PubMed ID: 33135516
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Wullenkord R; Friedrichs B; Erdmann T; Lenz G
Expert Rev Hematol; 2019 Dec; 12(12):1053-1062. PubMed ID: 31583927
[No Abstract] [Full Text] [Related]
3. The Role of PI3K Inhibition in Lymphoid Malignancies.
von Keudell G; Moskowitz AJ
Curr Hematol Malig Rep; 2019 Oct; 14(5):405-413. PubMed ID: 31359259
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase inhibitors in lymphoma.
Curran E; Smith SM
Curr Opin Oncol; 2014 Sep; 26(5):469-75. PubMed ID: 25024054
[TBL] [Abstract][Full Text] [Related]
5. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
7. Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Phillips TJ; Michot JM; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):8-20.e3. PubMed ID: 33132100
[TBL] [Abstract][Full Text] [Related]
8. Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.
Shan W; Wu G; Huang Y; Zeng H; Xia W; Lin Z; Xu B
Ann Hematol; 2022 Aug; 101(8):1741-1753. PubMed ID: 35688904
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
Seiler T; Hutter G; Dreyling M
Drugs; 2016 Apr; 76(6):639-46. PubMed ID: 27052260
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
11. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
13. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
Akinleye A; Avvaru P; Furqan M; Song Y; Liu D
J Hematol Oncol; 2013 Nov; 6(1):88. PubMed ID: 24261963
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
17. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
18. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
19. PI3K inhibitors for cancer therapy: what has been achieved so far?
Wu P; Liu T; Hu Y
Curr Med Chem; 2009; 16(8):916-30. PubMed ID: 19275602
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
